The mucosal layer of the gastrointestinal (GI) tract is able to resist digestion by the endogenous substances that we secrete to digest foodstuffs. So-called “mucosal defense” is multifactorial and can be modulated by a wide range of substances, many of which are classically regarded as inflammatory mediators. Damage to the GI mucosa, and its subsequent repair, are also modulated by various inflammatory mediators. In this article, we provide a review of some of the key Inflammatory mediators that modulate GI mucosal defense, Injury, and repair. Among the mediators discussed are nitric oxide, polyamines, the elcosanolds (prostaglandins and II-poxlns), protease-activated receptors, and cytokines. Many of these endogenous factors, or the enzymes involved in their synthesis, are considered potential therapeutic targets for the treatment of diseases of the digestive tract that are characterized by Inflammation and ulceration.
WallaceJL, GrangerDN. The cellular and molecular basis of gastric mucosal defence. FASEB J10: 731–740, 1996.
2.
PaimelaH, GoddardPJ, SilenW. Present views on restitution of gastrointestinal epithelium. Dig Dis Sci40: 2495–2496, 1995.
3.
HoffmannP, MazurkiewiczJ, HoltmannG, GerkenG, EysseleinVE, GoebellH. Capsaicin-sensitive nerve fibres induce epithelial cell proliferation, inflammatory cell immigration and transforming growth factor-alpha expression in the rat colonic mucosa in vivo. Scand J Gastroenterol37: 414–422, 2002.
4.
HolzerP, LivingstonEH, SariaA, GuthPH. Sensory neurons mediate protective vasodilatation in rat gastric mucosa. Am J Physiol260: G363–G370, 1991.
5.
SchmidtPT, LordalM, GazeliusB, HellstromPM. Tachykinins potently stimulate human small bowel blood flow: a laser Doppler flowmetry study in humans. Gut52: 53–56, 2003.
6.
BeckPL, McKnightW, LeeSS, WallaceJL. Prostaglandin modulation of the gastric vasculature and mucosal integrity in cirrhotic rats. Am J Physiol265: G453–G458, 1993.
7.
FerrazJGP, McKnightW, SharkeyKA, WallaceJL. Impaired vasodilatory responses in the gastric microcirculation of anesthetized rats with secondary biliary cirrhosis. Gastroenterology108: 1183–1191, 1995.
8.
VaneJR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol231: 232–235, 1971.
9.
RobertA. Antisecretory, antiulcer, cytoprotective and diarrheogenic properties of prostaglandins. Adv Prost Thrombox Res2: 507–520, 1976.
10.
WallaceJL. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology112: 1000–1016, 1997.
11.
AsakoH, KubesP, WallaceJL, GaginellaT, WolfRE, GrangerDN. Indomethacin induced leukocyte adhesion in mesenteric venules: role of lipoxygenase products. Am J Physiol262: G903–G908, 1992.
12.
AsakoH, KubesP, WallaceJL, WolfRE, GrangerDN. Modulation of leukocyte adhesion in rat mesenteric venules by aspirin and salicylate. Gastroenterology103: 146–152, 1992.
13.
KunkelSL, WigginsRC, ChensueSW, LarrickJ. Regulation of macrophage tumor necrosis factor production by prostaglandin E2. Biochem Biophys Res Commun137: 404–410, 1986.
KunkelSL, ChensueSW, PhanSH. Prostaglandins as endogenous mediators of interleukin 1 production. J Immunol136: 186–192, 1986.
16.
HamEA, SodermanDD, ZanettiME, DoughertyHW, McCauleyE, KuehlFA. Inhibition by prostaglandins of leukotriene B4 release from activated neutrophils. Proc Natl Acad Sci U S A80: 4349–4353, 1983.
17.
HaurandM, FlohL. Leukotriene formation by human polymorphonuclear leukocytes from endogenous arachidonate. Physiological triggers and modulation by prostanoids. Biochem Pharmacol38: 2129–2137, 1989.
18.
WertheimWA, KunkelSL, StandifordTJ, BurdickMD, BeckerFS, WilkeCA, GilbertAR, StrieterRM. Regulation of neutrophil-derived IL-8: the role of prostaglandin E2, dexamethasone, and IL-4. J Immunol151: 2166–2175, 1993.
19.
XieW, ChipmanJG, RobertsonDL, EriksonRL, SimmonsDL. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci U S A88: 2692–2696, 1991.
20.
KargmanS, CharlesonS, CartwrightM, FrankJ, RiendeauD, ManciniJ, EvansJ, O'neillG. Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Gastroenterology111: 445–454, 1996.
21.
DaviesNM, SharkeyKA, AsfahaS, MacnaughtonWK, WallaceJL. Aspirin causes rapid up-regulation of cyclo-oxygenase-2 expression in the stomach of rats. Aliment Pharmacol Ther11: 1101–1108, 1997.
22.
ZimmermanKC, SarbiaM, SchrorK, WeberAA. Constitutive cyclooxygenase-2 expression in healthy human and rabbit gastric mucosa. Mol Pharmacol54: 536–540, 1998.
23.
WallaceJL, DevchandPR. Emerging roles for cyclooxygenase-2 in gastrointetinal mucosal defence. Br J Pharmacol145: 275–282, 2005.
24.
WallaceJL, McKnightW, ReuterBK, VergnolleN. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology119: 706–714, 2000.
25.
GretzerB, MaricicN, RespondekM, SchuligoiR, PeskarBM. Effects of specific inhibition of cyclooxygenase-1 and cyclooxygenase-2 in the rat stomach with normal mucosa and after acid challenge. Br J Pharmacol132: 1565–1573, 2001.
26.
TanakaA, HaseS, MiyazawaT, TakeuchiK. Upregulation of cyclooxygenase-2 by inhibition of cyclooxygenase-1: a key to nonsteroidal anti-inflammatory drug-induced intestinal damage. J Pharm Exp Ther300: 754–761, 2002.
27.
SigthorssonG, SimpsonRJ, WalleyM, AnthonyA, FosterR, Hotz-BehoftsitzC, PalizbanA, PomboJ, WattsJ, MorhamSG, BjarnasonI. Cox-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice. Gastroenterology122: 1913–1923, 2002.
28.
MizunoH, SakamotoC, MatsudaK, WadaK, UchidaT, NoguchiH, AkamatsuT, KasugaM. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology112: 387–397, 1997.
29.
SchmassmannA, PeskarBM, StealerC, NetzerP, StroffT, FlogerziB, HalterF. Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastro-intestinal ulcer models in rats. Br J Pharmacol123: 795–804, 1998.
30.
HalterF, TarnawskiAS, SchmassmannA, PeskarBM. Cyclooxygenase 2—implications on maintenance of gastric mucosal integrity and ulcer healing: controversial issues and perspectives. Gut49: 443–453, 2001.
31.
MaL, Del Soldato, WallaceJL. Divergent effects of new cyclooxygenase inhibitors on gastric ulcer healing: shifting the angiogenic balance. Proc Natl Acad Sci U S A99: 13243–13247, 2002.
WallaceJL, ZamunerSR, McKnightW, DicayM, MencarelliA, Del SoldatoP, FiorucciS. Aspirin, but not NO-releasing aspirin (NCX-4016), interacts with selective Cox-2 inhibitors to aggravate gastric damage and inflammation. Am J Physiol286: G76–G81, 2004.
35.
SouzaMH, De LimaOM, ZamunerSR, FiorucciS, WallaceJL. Gastritis increases resistance to aspirin-induced mucosal injury via Cox-2-mediated lipoxin synthesis. Am J Physiol285: G54–G61, 2003.
36.
FiorucciS, SantucciL, WallaceJL, SardinaM, RomanoM, Del SoldatoP, MorelliA. Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosa. Proc Natl Acad Sci U S A100: 10937–10941, 2003.
37.
LaineL, MallerES, YuC, QuanH, SimonT. Ulcer formation with low-dose enteric-coated aspirin and the effect of Cox-2 selective inhibition: a double-blind trial. Gastroenterology127: 395–402, 2004.
38.
SerhanCN. Lipoxin biosynthesis and its impact in inflammatory and vascular events. Biochim Biophys Acta1212: 1–25, 1994.
39.
WallaceJL, MillerMJ. Nitric oxide in mucosal defense: a little goes a long way. Gastroenterology119: 512–520, 2000.
40.
WallaceJL. Cooperative modulation of gastrointestinal mucosal defence by prostaglandins and nitric oxide. Clin Invest Med19: 346–351, 1996.
41.
SandersKM, WardSM. Nitric oxide as a mediator of nonadrenergic noncholinergic neurotransmissionAm J Physiol262: G379–G392, 1992.
42.
MarcinkiewiczJ, ChainB, NowakB, GrabowskaA, BryniarskiK, BaranJ. Antimicrobial and cytotoxic activity of hypochlorous acid: interactions with taurine and nitrite. Inflamm Res49: 280–289, 2000.
43.
WhittleBJR, Lopez-BelmonteJ, MoncadaS. Regulation of gastric mucosal integrity by endogenous nitric oxide: interactions with prostanoids and sensory neuropeptides in the rat. Br J Pharmacol99: 607–611, 1990.
44.
MacNaughtonWK, CirinoG, WallaceJL. Endothelium-derived relaxing factor (nitric oxide) has protective actions in the stomach. Life Sci45: 1869–1876, 1989.
45.
WallaceJL, ReuterB, CicalaC, McKnightW, GrishamMB, CirinoG. Novel nonsterodial anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat. Gastroenterology107: 173–179, 1994.
46.
WallaceJL, ReuterB, CicalaC, McKnightW, GrishamMB, CirinoG. A diclofenac derivative without ulcerogenic properties. Eur J Pharmacol257: 249–255, 1994.
47.
WallaceJL, McKnightW, Del SoldatoP, BaydounAR, CirinoG. Antithrombotic effects of a nitric oxide-releasing, gastric-sparing aspirin derivative. J Clin Invest96: 2711–2718, 1995.
48.
ElliottSN, McKnightW, CirinoG, WallaceJL. A nitric oxide-releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in rats. Gastroenterology109: 524–530, 1995.
49.
RachmilewitzD, StamlerJS, KarmeliF, MullinsME, SingelDJ, LoscalzoJ, XavierRJ, PodolskyDK. Peroxynitrite-induced rat colitis—a new model of colonic inflammation. Gastroenterology105: 1681–1688, 1993.
50.
MillerMJS, ThompsonJH, ZhangXJ, Sadowska-KrowickaH, KakkisJL, MunshiUK, SandovalM, RossiJL, Eloby-ChildressS, BeckmanJS, YeYZ, RodiCP, ManningPT, CurrieMG, ClarkDA. Role of inducible nitric oxide synthase expression and peroxynitrite formation in guinea pig ileitis. Gastroenterology109: 1475–1483, 1995.
51.
HogaboamCM, JacobsonK, CollinsSM, BlennerhassettMG. The selective beneficial effects of nitric oxide inhibition in experimental colitis. Am J Physiol268: G673–G684, 1995.
52.
RachmilewitzD, KarmeliF, OkonE, BursztynM. Experimental colitis is ameliorated by inhibition of nitric oxide synthase activity. Gut37: 247–255, 1995.
53.
WallaceJL, VergnolleN, MuscaraMN, AsfahaS, ChapmanK, McKnightW, Del SoldatoP, MorelliA, FiorucciS. Enhanced anti-inflammatory effects of a nitric oxide-releasing derivative of mesal-amine in rats. Gastroenterology117: 557–566, 1999.
54.
JohnsonLR, McCormackSA. Healing of gastrointestinal mucosa: involvement of polyamines. News Physiol Sci14: 12–17, 1999.
ThomasT, KiangDT. Additive growth-inhibitory effects of dl-alpha-difluoromethylornithine and antiestrogens on Mcf-7 breast-cancer cell-line. Biochem Biophys Res Comm148: 1338–1345, 1987.
57.
McCormackSA, JohnsonLR. Role of polyamines in gastrointestinal mucosal growth. Am J Physiol260: G795–G806, 1991.
58.
WangJY, JohnsonLR, TsaiYH, CastroGA. Mucosal ornithine decarboxylase, polyamines, and hyperplasia in infected intestine. Am J Physiol260: G45–G51, 1991.
59.
GobertAP, ChengYL, AkhtarM, MerseyBD, BlumbergDR, CrossRK, ChaturvediR, DrachenbergCB, BoucherJL, HackerA, CaseroRA, WilsonKT. Protective role of arginase in a mouse model of colitis. J Immunol173: 2109–2117, 2004.
60.
MeleagrosL, GhateiMA, BloomSR. Release of vasodilator, but not vasoconstrictor, neuropeptides and of enteroglucagon by intestinal ischemia-reperfusion in the rat. Gut35: 1701–1706, 1994.
ThomasT, ThomasTJ. Polyamines in cell growth and cell death: molecular mechanisms and therapeutic applications. Cell Molec Life Sci58: 244–258, 2001.
63.
BousheyRP, YustaB, DruckerDJ. Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor. Cancer Research61: 687–693, 2001.
64.
EpsteinJB, GorskyM, GuglietlaA, LeN, SonisST. The correlation between epidermal growth factor levels in saliva and the severity of oral mucositis during oropharyngeal radiation therapy. Cancer89: 2258–2265, 2000.
65.
VergnolleN, WallaceJL, BunnettNW, HollenbergMD. Protease-activated receptors in inflammation, neuronal signaling and pain. Trends Pharmacol Sci22: 146–152, 2001.
66.
UeharaA, MuramotoK, TakadaH, SugawaraS. Neutrophil serine proteinases activate human nonepithelial cells to produce inflammatory cytokines through protease-activated receptor 2. J Immunol170: 5690–5696, 2003.
67.
PeiD. Matrix metalloproteinases target protease-activated receptors on the tumor cell surface. Cancer Cell7: 207–208, 2005.
68.
VergnolleN, MacnaughtonWK, Al-AniB, SaifeddineM, WallaceJL, HollenbergMD. Proteinase-activated receptor 2 (PAR2)-activating peptides: identification of a receptor distinct from PAR2 that regulates intestinal transport. Proc Natl Acad Sci U S A95: 7766–7771, 1998.
PlayfordRJ, GhoshS. Cytokines and growth factor modulators in intestinal inflammation and repair. J Pathol250: 417–425, 2005.
75.
DinarelloCA. Cytokines: interleukin-1 and tumour necrosis factor (cachectin). In: GallinJI, GoldsteinIM, SnydermanR, eds. Inflammation: Basic Principles and Clinical Correlates. New York: Raven Press, pp 195–208, 1988.
76.
DinarelloCA. The interleukin-1 family: 10 years of discovery. FASEB J8: 1314–1325, 1994.
77.
WallaceJL, KeenanCM, CucalaM, MugridgeKG, ParenteL. Mechanisms underlying the protective effects of interleukin-1 in experimental NSAID-gastropathy. Gastroenterology102: 1176–1185, 1992.
78.
ShibasakiT, YamauchiN, HottaM, ImakiT, OdaT, LingN, DemuraH. Interleukin-1 inhibits stress-induced gastric erosion in rats. Life Sci48: 2267–2273, 1991.
79.
WallaceJL, KeenanCM, MugridgeKG, ParenteL. Reduction of the severity of experimental gastric and duodenal ulceration by interleukin-1β. Eur J Pharmacol186: 279–284, 1990.
80.
UeharaA, OkumuraT, SekiyaC, OkamuraK, TakasugiY, NamikiM. Interleukin-1 inhibits the secretion of gastric acid in rats: possible involvement of prostaglandin. Biochem Biophys Res Commun162: 1578–1584, 1989.
81.
WallaceJL, CucalaM, MugridgeK, ParenteL. Secretagogue-specific effects of interleukin-1 on gastric acid secretion. Am J Physiol261: G559–G564, 1991.
82.
SaperasES, YangH, RivierC, TacheY. Central action of recombinant interleukin-1 to inhibit acid secretion in rats. Gastroenterology99: 1599–1606, 1990.
83.
WuKK, SandujaR, TsaiAL, FerhanogluB, Loose-MitchellDS. Aspirin inhibits interleukin 1-induced prostaglandin H synthase expression in cultured endothelial cells. Proc Natl Acad Sci U S A88: 2384–2387, 1991.
84.
PalmerRM, HickeryMS, CharlesIG, MoncadaS, BaylissMT. Induction of nitric oxide synthase in human chondrocytes. Biochem Biophys Res Commun193: 398–405, 1993.
85.
HogaboamCM, BefusAD, WallaceJL. Modulation of rat mast cell reactivity by IL-1 beta. Divergent effects on nitric oxide and platelet-activating factor release. J Immunol151: 3767–3774, 1993.
86.
SantucciL, FiorucciS, Di MatteoFM, MorelliA. Role of tumor necrosis factor alpha release and leukocyte margination in indomethacin-induced gastric injury in rats. Gastroenterology108: 393–401, 1995.
87.
AppleyardCB, McCaffertyDM, TigleyAW, SwainMG, WallaceJL. Tumour necrosis factor mediation of NSAID-induced gastric damage: role of leukocyte adherence. Am J Physiol270: G42–G48, 1996.
88.
HogaboamCM, BissonnetteEY, ChinBC, BefusAD, WallaceJL. Prostaglandins inhibit inflammatory mediator release from rat mast cells. Gastroenterology104: 122–129, 1993.
89.
FiorucciS, AntonelliE, SantucciL, MorelliO, MigliettiM, FedericiB, MannucciR, del SoldatoP, MorelliA. Gastrointestinal safety of nitric oxide-derived aspirin is related to inhibition of ICE-like cysteine proteases in rats. Gastroenterology116: 1089–1106, 1999.
90.
WallaceJL, FiorucciS, IgnarroLJ. Potential cardioprotective actions of NO-releasing aspirin. Nat Rev Drug Discov1: 375–382, 2002.
91.
FiorucciS, SantucciL, GreseleP. Faccino RM, del Soldato P, Morelli A. Gastrointestinal safely of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study. Gastroenterology124: 600–607, 2003.
